Search Within

Natalie Shapnik

Formats
  1. Meeting Abstract (9)
  2. Journal Article (6)
  3. Research Letter (1)
Groups
  1. Department of Medicine (16)
  2. Solid Tumor Oncology Division (16)
  3. Genitourinary Oncology Service (14)
  4. Weinberg Fellows (14)
  5. Hematologic Malignancies, Division of (13)
  6. Population Sciences Research Program (12)

More Groups

People
  1. Chung-Han Lee (14)
  2. Darren Feldman (14)
  3. Martin Voss (14)
  4. Robert Motzer (14)
  5. Ritesh Kotecha (13)
  6. Andrea Knezevic (12)

More People

Years
  1. 2023 (3)
  2. 2022 (5)
  3. 2021 (2)
  4. 2020 (3)
  5. 2019 (1)
  6. 2018 (2)
Publications
  1. Journal of Clinical Oncology (10)
  2. Gynecologic Oncology Reports (2)
  3. BMC Urology (1)
  4. Clinical Cancer Research (1)
  5. European Urology (1)
  6. JCO Precision Oncology (1)
Publishers
  1. American Society of Clinical Oncology (11)
  2. Elsevier B.V. (2)
  3. American Association for Cancer Research (1)
  4. Biomed Central Ltd (1)
  5. Elsevier Science, Inc. (1)

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma
    Meeting Abstract

    Fitzgerald, K. N.; Kotecha, R. R.; Knezevic, A.; Shapnik, N.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations
    Research Letter

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Matched molecular profiling of cell-free DNA and tumor tissue in patients with advanced clear cell renal cell carcinoma
    Journal Article

    Kotecha, R. R.; Gedvilaite, E.; Ptashkin, R.; Knezevic, A.; Murray, S.; Johnson, I.; Shapnik, N.; Feldman, D. R.; Carlo, M. I.; Shah, N. J.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Long-term outcomes of adrenal insufficiency (AI) due to anti-PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer
    Meeting Abstract

    Nguyen, B.; Shah, N. J.; Knezevic, A.; Newman, S.; Fitzgerald, K. N.; Kotecha, R.; Lee, C. H.; Carlo, M. I.; Aggen, D. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates
    Journal Article

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Zucker, M.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Dadoun, C.; Reznik, E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma
    Meeting Abstract

    Kotecha, R.; Lee, C. H.; McHugh, D. J.; Dadoun, C.; Knezevic, A.; Carlo, M. I.; Feld, E.; Shapnik, N.; Shah, N. J.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Reznik, E.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Tassone, D.; Dadoun, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma
    Journal Article

    Gleeson, J. P.; Nikolovski, I.; Dinatale, R.; Zucker, M.; Knezevic, A.; Patil, S.; Ged, Y.; Kotecha, R. R.; Shapnik, N.; Murray, S.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save